This is a phase II/III study of the use of recombinant human factor IX (rhFIX) in the treatment and prevention of bleeding in severe or moderate hemophilia B patients who have previously received blood products. The objectives are to assess the safety and efficacy of rhFIX administered by IV infusion in patients with severe or moderate hemophilia B during transfusion, or prevention of bleeding episodes, to estimate PK parameters of rhFIX for each patient and to monitor for any changes in PK parameters after repeated use of rhFIX.
Showing the most recent 10 out of 463 publications